A Phase II Study Evaluating the Efficacy and Tolerance of Combination Therapy of Imatinib Mesylate (IM) +-2A Interféron for Chronic Phase CML Patients Resistant or Refractory to IM Used as Single Therapy for at Least One Year
Interventional
Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label
Study the maintenance of a complete hematologic response, the cytogenetic and molecular responses, and the overall survival of the patients population
Mauricette MICHALLET, MD
Principal Investigator
Hospices Civils de Lyon
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
2003.317
NCT00146913
March 2004
Name | Location |
---|